Thymosin Alpha-1 Protects Gut, Liver, and Pancreas in Cystic Fibrosis Beyond Its Known Lung Benefits
Thymosin alpha-1 restored gut barrier integrity, immune homeostasis, and protected liver and pancreas in CF mice and metabolic syndrome models, demonstrating multi-organ anti-inflammatory benefits beyond the lungs.
Quick Facts
What This Study Found
Tα1 restored barrier integrity and immune homeostasis in inflamed CF mouse gut, protected pancreas and liver, and showed similar benefits in a metabolic syndrome model relevant to CF patients with high caloric intake.
Key Numbers
TA1 restored CFTR function and reduced inflammation in GI, hepatobiliary, and pancreatic CF manifestations.
How They Did This
Murine models of gut inflammation with clinical relevance for CF patients, including CF mice and metabolic syndrome mice. Assessed intestinal barrier integrity, immune homeostasis, and pancreatic/hepatic inflammation.
Why This Research Matters
As CF patients live longer due to new lung therapies (CFTR modulators), extra-pulmonary complications become increasingly important. Tα1's multi-organ anti-inflammatory effects could address gastrointestinal, hepatic, and pancreatic symptoms that significantly affect quality of life.
The Bigger Picture
Thymosin alpha-1 is already approved as an immune modulator in many countries. Demonstrating its benefits across multiple organ systems in CF positions it as a potential multi-target complementary therapy for this complex disease.
What This Study Doesn't Tell Us
Mouse models of CF and metabolic syndrome may not fully replicate human disease. Specific mechanisms of barrier protection not fully elucidated. Dosing, timing, and route optimization for human CF patients needed.
Questions This Raises
- ?Could Tα1 be added to CFTR modulator therapy for enhanced multi-system benefits?
- ?Would Tα1 help CF patients with pancreatic insufficiency or CF-related liver disease specifically?
- ?Is the metabolic syndrome protection relevant to CF patients on high-calorie diets?
Trust & Context
- Key Stat:
- Multi-organ Tα1 protected gut, liver, and pancreas in addition to previously demonstrated lung benefits in CF
- Evidence Grade:
- Preclinical evidence extending previous CF lung findings to extrapulmonary organs. Consistent anti-inflammatory effects across organ systems strengthen the case for clinical investigation.
- Study Age:
- Published in 2021. CF treatment continues to advance with CFTR modulators, and multi-system approaches like Tα1 could complement these therapies.
- Original Title:
- Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis.
- Published In:
- European journal of medicinal chemistry, 209, 112921 (2021)
- Authors:
- Bellet, Marina M(4), Borghi, Monica(2), Pariano, Marilena(4), Renga, Giorgia, Stincardini, Claudia, D'Onofrio, Fiorella, Brancorsini, Stefano, Garaci, Enrico, Costantini, Claudio, Romani, Luigina
- Database ID:
- RPEP-05277
Evidence Hierarchy
Frequently Asked Questions
Why does cystic fibrosis affect organs beyond the lungs?
The CFTR gene that's mutated in CF is expressed throughout the body, not just in the lungs. This causes thick mucus secretions and inflammation in the intestines, pancreas, liver, and other organs.
Is thymosin alpha-1 already used for cystic fibrosis?
Not yet specifically for CF, but Tα1 is approved in over 30 countries as an immune modulator. These preclinical findings suggest it could be investigated as a complementary therapy for the multi-system manifestations of CF.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05277APA
Bellet, Marina M; Borghi, Monica; Pariano, Marilena; Renga, Giorgia; Stincardini, Claudia; D'Onofrio, Fiorella; Brancorsini, Stefano; Garaci, Enrico; Costantini, Claudio; Romani, Luigina. (2021). Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis.. European journal of medicinal chemistry, 209, 112921. https://doi.org/10.1016/j.ejmech.2020.112921
MLA
Bellet, Marina M, et al. "Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis.." European journal of medicinal chemistry, 2021. https://doi.org/10.1016/j.ejmech.2020.112921
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha 1 exerts beneficial extrapulmonary effects in..." RPEP-05277. Retrieved from https://rethinkpeptides.com/research/bellet-2021-thymosin-alpha-1-exerts
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.